Evidence map›Paper›PMID 41329819›Full record

ArticleJournal of the American Chemical Society2025

Total Synthesis and Anticancer Study of (+)-Verticillin A.

Walker Knauss, Xiuqi Wang, Mariella G Filbin, Jun Qi, Mohammad Movassaghi

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Walker KnaussDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-1680-7904
Xiuqi WangCancer Biology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States.ORCID 0000-0002-8514-0410
Mariella G FilbinPediatric Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States.
Jun QiCancer Biology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States.ORCID 0000-0002-1461-3356
Mohammad MovassaghiDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-3080-1063

Funding

Synthesis and Study of Dimeric Diketopiperazine AlkaloidsR01GM089732 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MOVASSAGHI, MOHAMMAD · 2010 to 2021
$4.6M
Development of New Strategies for Chemical Synthesis and Study of Complex Natural ProductsR35GM141963 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Mohammad Movassaghi · 2021 to 2026
$4.3M
NIGMS NIH HHS R01 GM089732NIGMS NIH HHS R35 GM141963
6 · The paper itself

Abstract

We report the first total synthesis of (+)-verticillin A, over 50 years after the fungal metabolite was first isolated. Our initial strategy for sulfidation of a dimeric diketopiperazine (DKP) delivered the undesired stereochemistry for the epidithiodiketopiperazine (ETP) substructures of the alkaloid (+)-verticillin A. We later developed a protocol to directly introduce the disulfide with the correct relative stereochemistry on a complex DKP using benzhydryl hydrodisulfide prior to dimerization. Given the sensitivity of ETPs to carbon-centered radicals and UV irradiation, we developed a strategy to mask the disulfide as a pair of alkyl sulfides prior to an ambitious radical dimerization, fusing two bis-sulfide DKPs at the C3-C3' linkage, followed by photochemical N1 desulfonylation. A final-stage unveiling of the ETP substructures furnished (+)-verticillin A, the first dimeric ETP natural product containing C12 oxygenation to be accessed by total synthesis. (+)-Verticillin A and its

Indexed as

Antineoplastic AgentsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureStereoisomerismAntineoplastic Agents

Identifiers

PMID41329819
PMCPMC12764174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.